Pharma channel feed

As the maid­en biotech IPO on the HKEX fiz­zles, some in­vest­ment ex­perts see an up­side in tem­per­ing the hype

7 years ago
Financing
China

The boom­ing Boston/Cam­bridge biotech hub claims an in­dus­try-lead­ing role — no­body beats it at rais­ing record amounts of mon­ey

7 years ago

Tetraphase plots Q4 launch for first an­tibi­ot­ic af­ter long-await­ed OK for er­ava­cy­cline

7 years ago

Io­n­is, Akcea just got hand­ed a one-way tick­et to the end of the reg­u­la­to­ry line as the FDA re­jects volane­sors­en

7 years ago

The new Cin­derel­la sto­ry: Can­cer pow­er­house Genen­tech lines up an NK al­liance with Af­fimed loaded with bil­lions in biobucks

7 years ago

No­var­tis qui­et­ly hands top­i­cal treat­ment for rare dis­ease to Life­Max — lat­est in a string of out-li­cens­ing deals

7 years ago
R&D

Drug prices in ads: Sen­ate pass­es amend­ment

7 years ago

Jump­ing ahead of As­traZeneca, Ab­b­Vie and J&J get a green light to mar­ket Im­bru­vi­ca/Rit­ux­an com­bo for rare lym­phoma

7 years ago

No­var­tis wins a key OK for Kym­ri­ah, but con­tin­u­ing man­u­fac­tur­ing woes hob­ble roll­out — ri­val Gilead CAR-T breaks in­to Eu­rope

7 years ago

Shire wins a block­buster OK for pipeline star lanadelum­ab, boost­ing Take­da’s $62B takeover deal

7 years ago

Need a place­bo con­trol group for your next can­cer drug study? On­ly in cer­tain cir­cum­stances, says FDA

7 years ago

Sang­amo re­searcher charged with in­sid­er trad­ing in lat­est round of SEC ac­cu­sa­tions lev­eled at a biotech ex­ec

7 years ago
People

Once laud­ed for its clin­i­cal suc­cess, Roche casts off car­dio pro­gram in­clacum­ab for a mere $2M to Glob­al Blood Ther­a­peu­tics

7 years ago

TCR deal fren­zy con­tin­ues as blue­bird antes up $30M for new Grit­stone al­liance

7 years ago

Os­teoarthri­tis: FDA drafts guid­ance on de­vel­op­ing drugs, de­vices, bi­o­log­ics

7 years ago

Bris­tol-My­ers will sell Op­di­vo in Chi­na at half of US cost, set­ting prece­dent for check­point wave — re­port

7 years ago
China

Re­mem­ber mo­melo­tinib? Gilead un­loads shelved JAK in­hibitor for to­ken $3M pay­ment from its for­mer de­vel­op­ers

7 years ago

Costs ris­ing, As­traZeneca switch­es con­trac­tors and once again de­lays sched­uled com­ple­tion of its trou­bled $650M-plus HQ project

7 years ago

No­vo Nordisk turns to Evotec to build ear­ly-stage pipeline for di­a­betes, obe­si­ty drugs

7 years ago

$60M in, Ab­b­Vie is trig­ger­ing a $625M-plus plan to de­vel­op a new im­muno-on­col­o­gy drug that is go­ing af­ter GARP

7 years ago

FDA turns thumbs down on Al­ler­gan's op­ti­mistic case for uter­ine fi­broid drug as liv­er dam­age threat tor­pe­does ap­pli­ca­tion

7 years ago
R&D

As­traZeneca’s on­col­o­gy drug star Tagris­so gets a new ap­proval for front­line lung can­cer in Japan

7 years ago

FDA gives Mer­ck ‘re­al-time’ OK for Keytru­da, of­fer­ing a peek at the lat­est ex­ten­sion of the agen­cy's da­ta ex­press high­way

7 years ago

Har­bour Bio­Med jumps in­to the crowd­ed PD-1/L1 race, look­ing to take a Chi­nese as­set glob­al as check­point pipeline bulges

7 years ago
R&D
China
First page Previous page 293294295296297298299 Next page Last page
A service from the Financial Times